October 13, 2009

Johnson & Johnson Reports 2009 Third-Quarter Results:

Sales of $15.1 Billion Decreased 5.3% Versus 2008 Third Quarter
EPS of $1.20 increased 2.6% Versus 2008 Third Quarter

NEW BRUNSWICK, N.J., Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

Net earnings and diluted earnings per share for the third quarter of 2009 were $3.3 billion and $1.20, respectively, representing increases of 1.1% and 2.6%, as compared to the same period in 2008. The Company raised its earnings guidance for full-year 2009 to $4.54 - $4.59 per share, which excludes the impact of special items.

"We continue to successfully manage our broad base of businesses and deliver solid earnings despite the impact of patent expirations and the challenges posed by the current economic environment," said William C. Weldon, Chairman and Chief Executive Officer. "We completed multiple acquisitions and strategic collaborations and received several new product approvals in the quarter that will benefit patients worldwide and drive future growth."

Worldwide Consumer sales of $4.0 billion for the third quarter represented a decrease of 2.7% versus the prior year with an increase of 1.1% operationally and a negative impact from currency of 3.8%. Domestic sales decreased 4.4%; international sales decreased 1.4%, which reflected an operational increase of 5.2% and a negative currency impact of 6.6%.

Contributing to operational sales growth during the quarter were sales of Dabao skin care products; AVEENO® skin care products; SPLENDA® No Calorie Sweetener; Le Petit Marseillais® beauty care products; and LISTERINE® antiseptic mouthrinse. Other growth drivers were sales from the acquisition of Vania Expansion SNC.

Worldwide Pharmaceutical sales of $5.3 billion for the third quarter represented a decrease of 14.1% versus the prior year with an operational decline of 11.9% and a negative impact from currency of 2.2%. Domestic sales decreased 19.2%; international sales decreased 7.1%, which reflected an operational decrease of 1.9% and a negative currency impact of 5.2%.

REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases, demonstrated solid sales performance during the quarter. Several other pharmaceutical products had strong growth including PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; and RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment, an antipsychotic medication. Sales results of TOPAMAX® (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by generic competition.

During the quarter, the U.S. Food and Drug Administration (FDA) approved STELARA( ) (ustekinumab) for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The FDA also approved INVEGA® SUSTENNA (paliperidone palmitate) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults; the first once-monthly, long-acting, injectable atypical antipsychotic approved in the U.S. for this use. In addition, the FDA approved the Supplemental New Drug Application for INVEGA® (paliperidone) extended-release tablets for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants.

On Oct. 6, the European Commission approved SIMPONI (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis, active and progressive psoriatic arthritis and severe, active ankylosing spondylitis.

During the quarter, the Company completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program as well as an equity investment in Elan. Additionally, the Company announced that it had entered into a licensing and collaboration agreement with Gilead Sciences, Inc., for the development and commercialization of a new fixed dose combination of investigational compound TMC278 (rilpivirine hydrochloride 25 mg) and Gilead's TRUVADA® (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for treatment-naive adult patients with HIV-1.

Early in the fourth quarter, the Company announced that it had entered into a strategic collaboration with Crucell, N.V., focusing on the discovery, development and commercialization of monoclonal antibodies and vaccines for the treatment and prevention of influenza and other infectious and non-infectious diseases. The agreement also included an 18% equity investment in Crucell, N.V.

Worldwide Medical Devices and Diagnostics sales of $5.8 billion for the third quarter represented an increase of 2.3% versus the prior year with an operational increase of 4.1% and a negative currency impact of 1.8%. Domestic sales increased 4.5%; international sales increased 0.5%, which reflected an operational increase of 3.8% and a negative currency impact of 3.3%.

Primary contributors to the operational growth included Ethicon's surgical care and aesthetics products; Ethicon Endo-Surgery's minimally invasive products; DePuy's orthopaedic joint reconstruction, spine, and sports medicine businesses; and Ortho-Clinical Diagnostics' professional products. This growth was partially offset by lower sales in the Cordis franchise, reflecting strong competition in the drug-eluting stent market, and the 2008 divestiture of the Professional Wound Care products in our Ethicon business.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 117,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. The schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson can be found on the Company's website at www.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2008. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Supplementary Sales Data


    (Unaudited; Dollars in Millions)      THIRD QUARTER
    --------------------------------      -------------

                                                  Percent Change
                                                  --------------
                               2009   2008 Total   Operations  Currency
    ---------------------      ----   ---- -----   ----------  --------
    Sales to customers by
     segment of business

    Consumer
        U.S.                 $1,691  1,769  (4.4)%    (4.4)        -
        International         2,298  2,330  (1.4)      5.2      (6.6)
    -----------------         -----  -----  ----       ---      ----
                              3,989  4,099  (2.7)      1.1      (3.8)
                              -----  -----  ----       ---      ----

    Pharmaceutical
        U.S.                  2,857  3,538 (19.2)    (19.2)        -
        International         2,392  2,575  (7.1)     (1.9)     (5.2)
    -----------------         -----  -----  ----      ----      ----
                              5,249  6,113 (14.1)    (11.9)     (2.2)
                              -----  ----- -----     -----      ----

    Med Devices & Diagnostics
        U.S.                  2,766  2,648   4.5       4.5         -
        International         3,077  3,061   0.5       3.8      (3.3)
    -----------------         -----  -----   ---       ---      ----
                              5,843  5,709   2.3       4.1      (1.8)
                              -----  -----   ---       ---      ----

    U.S.                      7,314  7,955  (8.1)     (8.1)        -
    International             7,767  7,966  (2.5)      2.4      (4.9)
    -------------             -----  -----  ----       ---      ----
    Worldwide               $15,081 15,921  (5.3)%    (2.8)     (2.5)
    ---------               ------- ------  ----      ----      ----


    (Unaudited; Dollars in Millions)      NINE MONTHS
    --------------------------------      -----------

                                                  Percent Change
                                                  --------------
                               2009   2008 Total   Operations  Currency
    ---------------------      ----   ---- -----   ----------  --------
    Sales to customers by
     segment of business

    Consumer
        U.S.                 $5,125  5,282  (3.0)%    (3.0)         -
        International         6,429  6,917  (7.1)      4.1      (11.2)
    -----------------         -----  -----  ----       ---      -----
                             11,554 12,199  (5.3)      1.0       (6.3)
                             ------ ------  ----       ---       ----

    Pharmaceutical
        U.S.                  9,703 11,401 (14.9)    (14.9)         -
        International         6,824  7,481  (8.8)      1.4      (10.2)
    -----------------         -----  -----  ----       ---      -----
                             16,527 18,882 (12.5)     (8.5)      (4.0)
                             ------ ------ -----      ----       ----

    Med Devices & Diagnostics
        U.S.                  8,194  7,959   3.0       3.0          -
        International         9,071  9,525  (4.8)      3.7       (8.5)
    -----------------         -----  -----  ----       ---       ----
                             17,265 17,484  (1.3)      3.3       (4.6)
                             ------ ------  ----       ---       ----

    U.S.                     23,022 24,642  (6.6)     (6.6)         -
    International            22,324 23,923  (6.7)      3.1       (9.8)
    -------------            ------ ------  ----       ---       ----
    Worldwide               $45,346 48,565  (6.6)%    (1.8)      (4.8)
    ---------               ------- ------  ----      ----       ----



    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Supplementary Sales Data

    (Unaudited; Dollars in Millions)          THIRD QUARTER
    --------------------------------          -------------

                                                    Percent Change
                                                    --------------
                                 2009   2008 Total   Operations  Currency
    ---------------------        ----   ---- -----   ----------  --------
    Sales to customers by
     geographic area

    U.S.                       $7,314  7,955  (8.1)%     (8.1)        -
    ----                       ------  -----  ----       ----        --

    Europe                      3,879  4,076  (4.8)       2.1      (6.9)
    Western Hemisphere
     excluding U.S.             1,338  1,461  (8.4)       1.5      (9.9)
     Asia-Pacific, Africa       2,550  2,429   5.0        3.5       1.5
     --------------------       -----  -----   ---        ---       ---
    International               7,767  7,966  (2.5)       2.4      (4.9)
    -------------               -----  -----  ----        ---      ----

    Worldwide                 $15,081 15,921  (5.3)%     (2.8)     (2.5)
    ---------                 ------- ------  ----       ----      ----


    (Unaudited; Dollars in Millions)           NINE MONTHS
    --------------------------------           -----------

                                                    Percent Change
                                                    --------------
                                 2009   2008 Total   Operations  Currency
    ---------------------        ----   ---- -----   ----------  --------
    Sales to customers by
     geographic area

    U.S.                      $23,022 24,642  (6.6)%     (6.6)        -
    ----                      ------- ------  ----       ----        --

    Europe                     11,522 12,931 (10.9)       1.2     (12.1)
    Western Hemisphere
     excluding U.S.             3,615  3,986  (9.3)       5.8     (15.1)
     Asia-Pacific, Africa       7,187  7,006   2.6        5.1      (2.5)
     --------------------       -----  -----   ---        ---      ----
    International              22,324 23,923  (6.7)       3.1      (9.8)
    -------------              ------ ------  ----        ---      ----

    Worldwide                 $45,346 48,565  (6.6)%     (1.8)     (4.8)
    ---------                 ------- ------  ----       ----      ----



    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Condensed Consolidated Statement of Earnings


    (Unaudited; in Millions Except
     Per Share Figures)                     THIRD QUARTER
     ------------------                     -------------

                                 2009               2008
                            ----------------   ----------------     Percent
                                     Percent            Percent    Increase
                            Amount  to Sales   Amount  to Sales   (Decrease)
    ------------------      ------  --------   ------  --------   ---------
    Sales to customers     $15,081     100.0  $15,921     100.0        (5.3)
    ------------------     -------     -----  -------     -----        ----
    Cost of products sold    4,434      29.4    4,774      30.0        (7.1)
    Selling, marketing
     and administrative
     expenses                4,767      31.6    5,195      32.6        (8.2)
    Research expense         1,617      10.7    1,861      11.7       (13.1)
    Interest (income)
     expense, net              114       0.7       25       0.2
    Other (income)
     expense, net             (96)     (0.6)    (224)     (1.4)
    ---------------------      ---      ----     ----      ----        ----
    Earnings before
     provision for taxes
     on income               4,245      28.2    4,290      26.9        (1.0)
    Provision for taxes
     on income                 900       6.0      980       6.1        (8.2)
    -------------------        ---       ---      ---       ---        ----
    Net earnings            $3,345      22.2   $3,310      20.8         1.1
    ------------            ------      ----   ------      ----         ---

    Net earnings per
     share (Diluted)         $1.20              $1.17                   2.6

    Average shares
     outstanding (Diluted) 2,793.0            2,831.3

    Effective tax rate        21.2%              22.8%



    Johnson & Johnson and Subsidiaries
    ----------------------------------
    Condensed Consolidated Statement of Earnings

    (Unaudited; in Millions Except
     Per Share Figures)                       NINE MONTHS
     ------------------                       -----------

                            2009                 2008
                       ----------------   --------------------    Percent
                                Percent                Percent    Increase
                       Amount  to Sales   Amount      to Sales   (Decrease)
    ----------         ------  --------   ------      --------  ------------
    Sales to
     customers        $45,346     100.0  $48,565         100.0      (6.6)
    ----------        -------     -----  -------         -----      ----
    Cost of products
     sold              13,135      29.0   14,139          29.1      (7.1)
    Selling, marketing
     and administrative
     expenses          14,172      31.3   15,825          32.6     (10.4)
    Research expense    4,773      10.5    5,469          11.3     (12.7)
    In-process research
     & development          -         -       40           0.1
    Interest (income)
     expense, net         280       0.6       57           0.1
    Other (income)
     expense, net        (165)     (0.4)    (377)         (0.8)
    -----------------    ----      ----     ----          ----      ----
    Earnings before
     provision for
     taxes on income   13,151      29.0   13,412          27.6      (1.9)
    Provision for
     taxes on income    3,091       6.8    3,177           6.5      (2.7)
    ----------------    -----       ---    -----           ---      ----
    Net earnings      $10,060      22.2  $10,235          21.1      (1.7)
    ------------      -------      ----  -------          ----      ----


    Net earnings per
     share (Diluted)    $3.61              $3.60                     0.3

    Average shares
     outstanding
     (Diluted)        2,787.9            2,847.8

    Effective tax rate   23.5%              23.7%
    -----------------

    Adjusted earnings
     before provision
     for taxes and
     net earnings
         Earnings before
          provision for
          taxes on
          income      $13,151      29.0  $13,452 (1)      27.7      (2.2)
         Net earnings $10,060      22.2  $10,275 (1)      21.2      (2.1)
         Net earnings
          per share
          (Diluted)     $3.61              $3.61 (1)                 0.0
         Effective tax
          rate           23.5%              23.6%
          ----           ----               ----                     ---


    (1) The difference between as reported earnings and as adjusted earnings
        before provision for taxes on income and net earnings and net earnings
        per share (diluted) is IPR&D of $40 million with no tax benefit and
        $0.01 per share, respectively.


                           REPORTED SALES vs. PRIOR PERIOD ($MM)

                                      THIRD QUARTER
                                      -------------
                                               % Change
                                      -----------------------------------
                     2009   2008      Reported  Operational (1)  Currency
                     ----   ----      --------  ---------------  --------
    CONSUMER SEGMENT (2)
    ---------------------

    SKIN CARE
    ---------
    US                370    358          3.4%         3.4%          -
    Intl              472    500         -5.6%        -0.1%       -5.5%
    WW                842    858         -1.9%         1.3%       -3.2%

    BABY CARE
    ---------
    US                102    114        -10.5%       -10.5%          -
    Intl              442    472         -6.4%        -0.7%       -5.7%
    WW                544    586         -7.2%        -2.6%       -4.6%

    ORAL CARE
    ---------
    US                187    204         -8.3%        -8.3%          -
    Intl              223    230         -3.0%         4.8%       -7.8%
    WW                410    434         -5.5%        -1.4%       -4.1%

    OTC/NUTRITIONALS
    ----------------
    US                732    778         -5.9%        -5.9%          -
    Intl              666    661          0.8%         8.0%       -7.2%
    WW              1,398  1,439         -2.8%         0.5%       -3.3%

    WOMEN'S HEALTH
    --------------
    US                142    164        -13.4%       -13.4%          -
    Intl              360    346          4.0%        11.7%       -7.7%
    WW                502    510         -1.6%         3.6%       -5.2%

    WOUND CARE / OTHER
    ------------------
    US                158    151          4.6%         4.6%          -
    Intl              135    121         11.6%        18.0%       -6.4%
    WW                293    272          7.7%        10.5%       -2.8%

    TOTAL CONSUMER
    --------------
    US              1,691  1,769         -4.4%        -4.4%          -
    Intl            2,298  2,330         -1.4%         5.2%       -6.6%
    WW              3,989  4,099         -2.7%         1.1%       -3.8%



                                       NINE MONTHS
                                       -----------
                                               % Change
                                      -----------------------------------
                     2009   2008      Reported  Operational (1)  Currency
                     ----   ----      --------  ---------------  --------
    CONSUMER SEGMENT (2)
    ---------------------

    SKIN CARE
    ---------
    US              1,204  1,119          7.6%         7.6%          -
    Intl            1,313  1,418         -7.4%         3.0%      -10.4%
    WW              2,517  2,537         -0.8%         5.0%       -5.8%

    BABY CARE
    ---------
    US                308    340         -9.4%        -9.4%          -
    Intl            1,233  1,351         -8.7%         0.7%       -9.4%
    WW              1,541  1,691         -8.9%        -1.4%       -7.5%

    ORAL CARE
    ---------
    US                549    588         -6.6%        -6.6%          -
    Intl              612    640         -4.4%         8.3%      -12.7%
    WW              1,161  1,228         -5.5%         1.1%       -6.6%

    OTC/NUTRITIONALS
    ----------------
    US              2,137  2,299         -7.0%        -7.0%          -
    Intl            1,919  2,139        -10.3%         1.8%      -12.1%
    WW              4,056  4,438         -8.6%        -2.8%       -5.8%

    WOMEN'S HEALTH
    --------------
    US                443    470         -5.7%        -5.7%          -
    Intl              963  1,005         -4.2%         7.2%      -11.4%
    WW              1,406  1,475         -4.7%         3.1%       -7.8%

    WOUND CARE / OTHER
    ------------------
    US                484    466          3.9%         3.9%          -
    Intl              389    364          6.9%        18.8%      -11.9%
    WW                873    830          5.2%        10.5%       -5.3%

    TOTAL CONSUMER
    --------------
    US              5,125  5,282         -3.0%        -3.0%          -
    Intl            6,429  6,917         -7.1%         4.1%      -11.2%
    WW             11,554 12,199         -5.3%         1.0%       -6.3%


    * See footnotes below


                                        THIRD QUARTER
                                        -------------

                                                 % Change
                                                 --------
                       2009   2008     Reported  Operational (1)  Currency
                       ----   ----     --------  ---------------  --------
    PHARMACEUTICAL SEGMENT  (2)
    ---------------------------

    ACIPHEX/PARIET
    --------------
    US                  131    130          0.8%         0.8%          -
    Intl                130    152        -14.5%        -9.0%       -5.5%
    WW                  261    282         -7.4%        -4.4%       -3.0%

    CONCERTA
    --------
    US                  205    190          7.9%         7.9%          -
    Intl                 79    208        -62.0%       -59.2%       -2.8%
    WW                  284    398        -28.6%       -27.2%       -1.4%

    DURAGESIC/FENTANYL TRANSDERMAL
    ------------------------------
    US                   38     54        -29.6%       -29.6%          -
    Intl                168    205        -18.0%       -15.2%       -2.8%
    WW                  206    259        -20.5%       -18.3%       -2.2%

    LEVAQUIN/FLOXIN
    ---------------
    US                  294    313         -6.1%        -6.1%          -
    Intl                 17     20        -15.0%         0.3%      -15.3%
    WW                  311    333         -6.6%        -5.7%       -0.9%

    PROCRIT/EPREX
    --------------
    US                  299    334        -10.5%       -10.5%          -
    Intl                243    285        -14.7%        -9.6%       -5.1%
    WW                  542    619        -12.4%       -10.0%       -2.4%

    RAZADYNE/REMINYL
    ----------------
    US                    1     31        -96.8%       -96.8%          -
    Intl                 96    107        -10.3%        -3.8%       -6.5%
    WW                   97    138        -29.7%       -24.7%       -5.0%

    REMICADE
    --------
    US                  822    778          5.7%         5.7%          -
    US Exports (4)      208    198          5.1%         5.1%          -
    Intl                  6      2        200.0%       198.7%        1.3%
    WW                1,036    978          5.9%         5.9%          -

    RISPERDAL/RISPERIDONE
    ----------------------
    US                   35    122        -71.3%       -71.3%          -
    Intl                157    198        -20.7%       -21.4%        0.7%
    WW                  192    320        -40.0%       -40.4%        0.4%

    RISPERDAL CONSTA
    ----------------
    US                  129    118          9.3%         9.3%          -
    Intl                224    220          1.8%        10.2%       -8.4%
    WW                  353    338          4.4%         9.9%       -5.5%

    TOPAMAX
    -------
    US                   72    606        -88.1%       -88.1%          -
    Intl                103    122        -15.6%        -7.9%       -7.7%
    WW                  175    728        -76.0%       -74.7%       -1.3%

    VELCADE
    -------
    US                    -      1       -100.0%      -100.0%          -
    Intl                231    189         22.2%        31.1%       -8.9%
    WW                  231    190         21.6%        30.5%       -8.9%

    OTHER
    -----
    US                  623    663         -6.0%        -6.0%          -
    Intl                938    867          8.2%        13.6%       -5.4%
    WW                1,561  1,530          2.0%         5.1%       -3.1%

    TOTAL PHARMACEUTICAL
    --------------------
    US                2,857  3,538        -19.2%       -19.2%          -
    Intl              2,392  2,575         -7.1%        -1.9%       -5.2%
    WW                5,249  6,113        -14.1%       -11.9%       -2.2%


    MAJOR NEW PHARM PRODUCTS (5)
    ----------------------------

    PREZISTA
    --------
    US                   78     34        129.4%       129.4%          -
    Intl                 73     45         62.2%        77.0%      -14.8%
    WW                  151     79         91.1%        99.5%       -8.4%

    INVEGA
    ------
    US                   61     73        -16.4%       -16.4%          -
    Intl                 36     16        125.0%       142.5%      -17.5%
    WW                   97     89          9.0%        12.3%       -3.3%



                                         NINE MONTHS
                                         -----------
                                                   % Change
                                        -----------------------------------
                       2009   2008      Reported  Operational (1)  Currency
                       ----   ----      --------  ---------------  --------
    PHARMACEUTICAL SEGMENT  (2)
    ---------------------------

    ACIPHEX/PARIET
    --------------
    US                  397    399         -0.5%        -0.5%          -
    Intl                387    485        -20.2%        -9.3%      -10.9%
    WW                  784    884        -11.3%        -5.3%       -6.0%

    CONCERTA
    --------
    US                  707    622         13.7%        13.7%          -
    Intl                238    345        -31.0%       -20.8%      -10.2%
    WW                  945    967         -2.3%         1.3%       -3.6%

    DURAGESIC/FENTANYL TRANSDERMAL
    ------------------------------
    US                  163    199        -18.1%       -18.1%          -
    Intl                492    565        -12.9%        -4.3%       -8.6%
    WW                  655    764        -14.3%        -8.0%       -6.3%

    LEVAQUIN/FLOXIN
    ---------------
    US                1,045  1,117         -6.4%        -6.4%          -
    Intl                 53     63        -15.9%         1.4%      -17.3%
    WW                1,098  1,180         -6.9%        -6.0%       -0.9%

    PROCRIT/EXPREX
    --------------
    US                  950  1,014         -6.3%        -6.3%          -
    Intl                719    886        -18.8%        -9.0%       -9.8%
    WW                1,669  1,900        -12.2%        -7.6%       -4.6%

    RAZADYNE/REMINYL
    ----------------
    US                   30    123        -75.6%       -75.6%          -
    Intl                275    316        -13.0%        -1.2%      -11.8%
    WW                  305    439        -30.5%       -22.0%       -8.5%

    REMICADE
    --------
    US                2,330  2,138          9.0%         9.0%          -
    US Exports (4)      821    718         14.3%        14.3%          -
    Intl                 15      6        150.0%       145.8%        4.2%
    WW                3,166  2,862         10.6%        10.6%          -

    RISPERDAL/RISPERIDONE
    ----------------------
    US                  223  1,196        -81.4%       -81.4%          -
    Intl                483    645        -25.1%       -21.3%       -3.8%
    WW                  706  1,841        -61.7%       -60.4%       -1.3%

    RISPERDAL CONSTA
    ----------------
    US                  386    339         13.9%        13.9%          -
    Intl                640    651         -1.7%        12.6%      -14.3%
    WW                1,026    990          3.6%        13.0%       -9.4%

    TOPAMAX
    -------
    US                  642  1,674        -61.6%       -61.6%          -
    Intl                317    377        -15.9%        -3.5%      -12.4%
    WW                  959  2,051        -53.2%       -50.9%       -2.3%

    VELCADE
    -------
    US                    -      4       -100.0%      -100.0%          -
    Intl                652    575         13.4%        26.7%      -13.3%
    WW                  652    579         12.6%        25.8%      -13.2%

    OTHER
    -----
    US                2,009  1,858          8.1%         8.1%          -
    Intl              2,553  2,567         -0.5%         9.2%       -9.7%
    WW                4,562  4,425          3.1%         8.8%       -5.7%

    TOTAL PHARMACEUTICAL
    --------------------
    US                9,703 11,401        -14.9%       -14.9%          -
    Intl              6,824  7,481         -8.8%         1.4%      -10.2%
    WW               16,527 18,882        -12.5%        -8.5%       -4.0%


    MAJOR NEW PHARM PRODUCTS (5)
    ----------------------------

    PREZISTA
    --------
    US                  215    109         97.2%        97.2%          -
    Intl                198    132         50.0%        70.0%      -20.0%
    WW                  413    241         71.4%        82.3%      -10.9%

    INVEGA
    ------
    US                  194    192          1.0%         1.0%          -
    Intl                 93     39        138.5%       168.1%      -29.6%
    WW                  287    231         24.2%        29.2%       -5.0%

    * See footnotes below


                                      THIRD QUARTER
                                      -------------
                                                 % Change
                                      -----------------------------------
                     2009   2008      Reported  Operational (1)  Currency
                     ----   ----      --------  ---------------  --------
    MEDICAL DEVICES
     AND DIAG (2) (3)
    -----------------

    CORDIS (6)
    ----------
    US                233    259        -10.0%       -10.0%          -
    Intl              407    431         -5.6%        -4.6%       -1.0%
    WW                640    690         -7.2%        -6.6%       -0.6%

    DEPUY
    -----
    US                740    698          6.0%         6.0%          -
    Intl              544    533          2.1%         7.6%       -5.5%
    WW              1,284  1,231          4.3%         6.7%       -2.4%

    DIABETES CARE
    -------------
    US                332    349         -4.9%        -4.9%          -
    Intl              302    318         -5.0%        -0.4%       -4.6%
    WW                634    667         -4.9%        -2.7%       -2.2%

    ETHICON
    -------
    US                439    372         18.0%        18.0%          -
    Intl              580    585         -0.9%         3.8%       -4.7%
    WW              1,019    957          6.5%         9.4%       -2.9%

    ETHICON ENDO-SURGERY
    --------------------
    US                499    473          5.5%         5.5%          -
    Intl              607    569          6.7%        10.9%       -4.2%
    WW              1,106  1,042          6.1%         8.4%       -2.3%

    ORTHO-CLINICAL DIAGNOSTICS
    --------------------------
    US                285    261          9.2%         9.2%          -
    Intl              216    209          3.3%         7.0%       -3.7%
    WW                501    470          6.6%         8.2%       -1.6%

    VISION CARE
    -----------
    US                238    236          0.8%         0.8%          -
    Intl              421    416          1.2%        -0.2%        1.4%
    WW                659    652          1.1%         0.2%        0.9%

    TOTAL MEDICAL DEVICES AND DIAG
    ------------------------------
    US              2,766  2,648          4.5%         4.5%          -
    Intl            3,077  3,061          0.5%         3.8%       -3.3%
    WW              5,843  5,709          2.3%         4.1%       -1.8%


                                         NINE MONTHS
                                         -----------
                                               % Change
                                      -----------------------------------
                     2009   2008      Reported  Operational (1)  Currency
                     ----   ----      --------  ---------------  --------
    MEDICAL DEVICES
     AND DIAG (2) (3)
    -----------------

    CORDIS (6)
    ----------
    US                731    929        -21.3%       -21.3%          -
    Intl            1,251  1,375         -9.0%        -3.9%       -5.1%
    WW              1,982  2,304        -14.0%       -10.9%       -3.1%

    DEPUY
    -----
    US              2,268  2,129          6.5%         6.5%          -
    Intl            1,631  1,717         -5.0%         6.8%      -11.8%
    WW              3,899  3,846          1.4%         6.7%       -5.3%

    DIABETES CARE
    -------------
    US                908    990         -8.3%        -8.3%          -
    Intl              877    966         -9.2%         0.2%       -9.4%
    WW              1,785  1,956         -8.7%        -4.1%       -4.6%

    ETHICON
    -------
    US              1,296  1,087         19.2%        19.2%          -
    Intl            1,717  1,835         -6.4%         3.6%      -10.0%
    WW              3,013  2,922          3.1%         9.3%       -6.2%

    ETHICON ENDO-SURGERY
    --------------------
    US              1,442  1,386          4.0%         4.0%          -
    Intl            1,794  1,783          0.6%        10.6%      -10.0%
    WW              3,236  3,169          2.1%         7.7%       -5.6%

    ORTHO-CLINICAL DIAGNOSTICS
    --------------------------
    US                846    749         13.0%        13.0%          -
    Intl              616    640         -3.8%         4.8%       -8.6%
    WW              1,462  1,389          5.3%         9.3%       -4.0%

    VISION CARE
    -----------
    US                703    689          2.0%         2.0%          -
    Intl            1,185  1,209         -2.0%         0.3%       -2.3%
    WW              1,888  1,898         -0.5%         0.9%       -1.4%

    TOTAL MEDICAL DEVICES AND DIAG
    ------------------------------
    US              8,194  7,959          3.0%         3.0%          -
    Intl            9,071  9,525         -4.8%         3.7%       -8.5%
    WW             17,265 17,484         -1.3%         3.3%       -4.6%


    (1) Operational growth excludes the effect of currency
    (2) Select areas (unaudited)
    (3) Prior year amounts have been reclassified to conform with current
        presentation
    (4) For external purposes, reported as U.S. sales
    (5) Included in Other
    (6) Includes sales of Drug-Eluting Stents for Q3 2009 of $53, $158 and
        $211MM Domestic, International and Worldwide respectively

        Includes sales of Drug-Eluting Stents for Q3 2008 of $97, $192 and
        $289MM Domestic, International and Worldwide respectively

        Includes sales of Drug-Eluting Stents for September YTD 2009 of $189,
        $507 and $696MM Domestic, International and Worldwide respectively

        Includes sales of Drug-Eluting Stents for September YTD 2008 of $433,
        $650 and $1,083MM  Domestic, International and Worldwide respectively


SOURCE Johnson & Johnson

 
http://www.jnj.com

Copyright © 2009 PR Newswire. All rights reserved


Close window | Back to top

Copyright 2014 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.